UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diagnosis and Management of Primary Bone Tumors: Volume 2

Bahk, Won-Jong

1, 2023

Volltextzugriff (PDF)

Descriptive analysis and prognostic factors in cats with myeloma‐related disorders: A multicenter retrospective study of 50 cases

Journal of veterinary internal medicine, 2024-05, Vol.38 (3), p.1693-1705

2024

Volltextzugriff (PDF)

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Cell metabolism, 2021-01, Vol.33 (1), p.78-93.e7

2021

Volltextzugriff (PDF)

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S571-S572

2024

Volltextzugriff (PDF)

Bone marrow transplantation generates T cell-dependent control of myeloma in mice

The Journal of clinical investigation, 2019-01, Vol.129 (1), p.106-121

2019

Volltextzugriff (PDF)

MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S476-S477

2023

Volltextzugriff (PDF)

Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade

Blood, 2018-10, Vol.132 (16), p.1675-1688

2018

Volltextzugriff (PDF)

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

The Journal of clinical investigation, 2023-02, Vol.133 (4), p.1-11

2023

Volltextzugriff (PDF)

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

Leukemia, 2017-12, Vol.31 (12), p.2642-2651

2017

Volltextzugriff (PDF)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Frontiers in oncology, 2021-02, Vol.10, p.624661-624661

2021

Volltextzugriff (PDF)

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

Cell cycle (Georgetown, Tex.), 2018-01, Vol.17 (7), p.858-867

2018

Volltextzugriff (PDF)

Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question

British journal of haematology, 2024-04, Vol.204 (4), p.1141-1142

2024

Volltextzugriff (PDF)

EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

Hematological oncology, 2023-06, Vol.41 (S2), p.778-779

2023

Volltextzugriff (PDF)

Oral manifestations of multiple myeloma – A systematic review

Oral oncology reports, 2024-06, Vol.10, p.100485, Article 100485

2024

Volltextzugriff (PDF)

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

Neoplasia (New York, N.Y.), 2019-08, Vol.21 (8), p.777-787

2019

Volltextzugriff (PDF)

How I treat the young patient with multiple myeloma

Blood, 2018-09, Vol.132 (11), p.1114-1124

2018

Volltextzugriff (PDF)

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

The Journal of clinical investigation, 2015-05, Vol.125 (5), p.2077-2089

2015

Volltextzugriff (PDF)

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma

The Journal of immunology (1950), 2013-06, Vol.190 (11), p.5620-5628

2013

Volltextzugriff (PDF)

MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S505-S505

2023

Volltextzugriff (PDF)

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S478-S479

2023

Volltextzugriff (PDF)

MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S477-S478

2023

Volltextzugriff (PDF)

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S480-S481

2023

Volltextzugriff (PDF)

MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S484-S484

2023

Volltextzugriff (PDF)

MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S480-S480

2023

Volltextzugriff (PDF)

MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S477-S477

2023

Volltextzugriff (PDF)

1 – 25 von 25.033

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14.289)
Mit Volltextzugriff
(15.799)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Multiple Myeloma
(23.145)
Science & Technology
(10.324)
Life Sciences & Biomedicine
(9.750)
Oncology
(5.347)
Patients
(4.277)
Hematology
(4.070)
Cancer
(3.346)
Bone Marrow
(3.091)
Lymphoma
(2.354)
Proteins
(2.338)
Cancer Therapies
(2.305)
Clinical Trials
(2.303)
Chemotherapy
(2.289)
Leukemia
(2.248)
Tumors
(2.192)
Care And Treatment
(1.783)
Animals
(1.777)
Immunotherapy
(1.758)
Medical Prognosis
(1.585)
Medical Research
(1.571)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(10.617)
Nexis Uni
(8.072)
Ingenta
(7.989)
Journals@Ovid Ovid Full Text
(4.648)
IngentaConnect Journals
(4.630)
Springer Nature - Complete Springer Journals
(3.076)
MEDLINE
(2.451)
Wiley Online Library - AutoHoldings Journals
(1.874)
Publisher or Other Site
(1.783)
Elsevier ScienceDirect Journals Complete
(1.720)
Wiley Online Library
(1.146)
North East Research Libraries Nature Academic Titles
(926)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(904)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(857)
Taylor & Francis Journals Auto-Holdings Collection
(766)
Taylor & Francis
(467)
Taylor & Francis:Master (3349 titles)
(398)
EBSCOhost Business Source Ultimate
(396)
BMJ Publishing
(370)
ProQuest Dissertations & Theses A&I
(361)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Reactions Weekly
(1.239)
Pr Newswire
(939)
Business Wire
(783)
Cancers
(600)
Clinical Lymphoma, Myeloma And Leukemia
(356)
Curēus
(305)
M2 Presswire
(273)
Frontiers In Oncology
(271)
British Journal Of Haematology
(218)
Oncology Letters
(181)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Diagnosis and Management of Primary Bone Tumors: Volume 2

Descriptive analysis and prognostic factors in cats with myeloma‐related disorders: A multicenter retrospective study of 50 cases

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

Bone marrow transplantation generates T cell-dependent control of myeloma in mice

MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results

Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question

EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

Oral manifestations of multiple myeloma – A systematic review

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

How I treat the young patient with multiple myeloma

Immunosurveillance and therapy of multiple myeloma are CD226 dependent

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma

MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study

MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis

MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Aktive Filter

Suchergebnisse filtern